A citation-based method for searching scientific literature

Yongli Ji, Cathryn Rankin, Steven Grunberg, Andy E Sherrod, Jamshid Ahmadi, Jeannette J Townsend, Lynn G Feun, Ruth K Fredericks, Christy A Russell, Fairooz F Kabbinavar, Keith J Stelzer, Anne Schott, Claire Verschraegen. J Clin Oncol 2015
Times Cited: 65







List of co-cited articles
706 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma.
Thomas J Kaley, Patrick Wen, David Schiff, Keith Ligon, Sam Haidar, Sasan Karimi, Andrew B Lassman, Craig P Nolan, Lisa M DeAngelis, Igor Gavrilovic,[...]. Neuro Oncol 2015
143
47

Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO.
Victoria E Clark, E Zeynep Erson-Omay, Akdes Serin, Jun Yin, Justin Cotney, Koray Ozduman, Timuçin Avşar, Jie Li, Phillip B Murray, Octavian Henegariu,[...]. Science 2013
496
43

Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations.
Priscilla K Brastianos, Peleg M Horowitz, Sandro Santagata, Robert T Jones, Aaron McKenna, Gad Getz, Keith L Ligon, Emanuele Palescandolo, Paul Van Hummelen, Matthew D Ducar,[...]. Nat Genet 2013
383
41

Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma.
Malak Abedalthagafi, Wenya Linda Bi, Ayal A Aizer, Parker H Merrill, Ryan Brewster, Pankaj K Agarwalla, Marc L Listewnik, Dora Dias-Santagata, Aaron R Thorner, Paul Van Hummelen,[...]. Neuro Oncol 2016
154
36

Atypical and anaplastic meningiomas treated with bevacizumab.
Lakshmi Nayak, Fabio M Iwamoto, Jeremy D Rudnick, Andrew D Norden, Eudocia Quant Lee, Jan Drappatz, Antonio Omuro, Thomas J Kaley. J Neurooncol 2012
110
36

A phase II trial of PTK787/ZK 222584 in recurrent or progressive radiation and surgery refractory meningiomas.
Jeffrey J Raizer, Sean A Grimm, Alfred Rademaker, James P Chandler, Kenji Muro, Irene Helenowski, Laurie Rice, Katie McCarthy, Sandra K Johnston, Maciej M Mrugala,[...]. J Neurooncol 2014
61
36

Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review.
Thomas Kaley, Igor Barani, Marc Chamberlain, Michael McDermott, Katherine Panageas, Jeffrey Raizer, Leland Rogers, David Schiff, Michael Vogelbaum, Damien Weber,[...]. Neuro Oncol 2014
126
32

Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma.
Andrew D Norden, Keith L Ligon, Samantha N Hammond, Alona Muzikansky, David A Reardon, Thomas J Kaley, Tracy T Batchelor, Scott R Plotkin, Jeffrey J Raizer, Eric T Wong,[...]. Neurology 2015
51
41

Temozolomide for treatment-resistant recurrent meningioma.
Marc C Chamberlain, Denice D Tsao-Wei, Susan Groshen. Neurology 2004
101
32

Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series.
Emil Lou, Ashley L Sumrall, Scott Turner, Katherine B Peters, Annick Desjardins, James J Vredenburgh, Roger E McLendon, James E Herndon, Frances McSherry, Julie Norfleet,[...]. J Neurooncol 2012
114
32

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.
David N Louis, Arie Perry, Guido Reifenberger, Andreas von Deimling, Dominique Figarella-Branger, Webster K Cavenee, Hiroko Ohgaki, Otmar D Wiestler, Paul Kleihues, David W Ellison. Acta Neuropathol 2016
32

TERT Promoter Mutations and Risk of Recurrence in Meningioma.
Felix Sahm, Daniel Schrimpf, Adriana Olar, Christian Koelsche, David Reuss, Juliane Bissel, Annekathrin Kratz, David Capper, Sebastian Schefzyk, Thomas Hielscher,[...]. J Natl Cancer Inst 2015
194
30

DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis.
Felix Sahm, Daniel Schrimpf, Damian Stichel, David T W Jones, Thomas Hielscher, Sebastian Schefzyk, Konstantin Okonechnikov, Christian Koelsche, David E Reuss, David Capper,[...]. Lancet Oncol 2017
341
30


Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma.
Steven M Grunberg, Martin H Weiss, Christy A Russell, Irving M Spitz, Jamshid Ahmadi, Alfredo Sadun, Regine Sitruk-Ware. Cancer Invest 2006
108
26

Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).
Patrick Y Wen, W K Alfred Yung, Kathleen R Lamborn, Andrew D Norden, Timothy F Cloughesy, Lauren E Abrey, Howard A Fine, Susan M Chang, H Ian Robins, Karen Fink,[...]. Neuro Oncol 2009
90
26

Recurrent meningioma: salvage therapy with long-acting somatostatin analogue.
Marc C Chamberlain, Michael J Glantz, Camilo E Fadul. Neurology 2007
121
26

Recurrent high-grade meningioma: a phase II trial with somatostatin analogue therapy.
Marta Simó, Andreas A Argyriou, Miquel Macià, Gerard Plans, Carles Majós, Noemi Vidal, Miguel Gil, Jordi Bruna. Cancer Chemother Pharmacol 2014
40
42

A phase II trial of bevacizumab and everolimus as treatment for patients with refractory, progressive intracranial meningioma.
Kent C Shih, Sajeel Chowdhary, Paul Rosenblatt, Alva B Weir, Gregg C Shepard, Jeffrey T Williams, Mythili Shastry, Howard A Burris, John D Hainsworth. J Neurooncol 2016
52
32

Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review.
Leland Rogers, Igor Barani, Marc Chamberlain, Thomas J Kaley, Michael McDermott, Jeffrey Raizer, David Schiff, Damien C Weber, Patrick Y Wen, Michael A Vogelbaum. J Neurosurg 2015
311
24

Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma.
Andrew D Norden, Jeffrey J Raizer, Lauren E Abrey, Kathleen R Lamborn, Andrew B Lassman, Susan M Chang, W K Alfred Yung, Mark R Gilbert, Howard A Fine, Minesh Mehta,[...]. J Neurooncol 2010
108
24

EANO guidelines for the diagnosis and treatment of meningiomas.
Roland Goldbrunner, Giuseppe Minniti, Matthias Preusser, Michael D Jenkinson, Kita Sallabanda, Emmanuel Houdart, Andreas von Deimling, Pantelis Stavrinou, Florence Lefranc, Morten Lund-Johansen,[...]. Lancet Oncol 2016
390
24

Hydroxyurea with or without imatinib in the treatment of recurrent or progressive meningiomas: a randomized phase II trial by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
Elena Mazza, Alba Brandes, Silvia Zanon, Marika Eoli, Giuseppe Lombardi, Marina Faedi, Enrico Franceschi, Michele Reni. Cancer Chemother Pharmacol 2016
23
65


Recurrent somatic mutations in POLR2A define a distinct subset of meningiomas.
Victoria E Clark, Akdes Serin Harmancı, Hanwen Bai, Mark W Youngblood, Tong Ihn Lee, Jacob F Baranoski, A Gulhan Ercan-Sencicek, Brian J Abraham, Abraham S Weintraub, Denes Hnisz,[...]. Nat Genet 2016
176
23

A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a Southwest Oncology Group study.
J W Goodwin, J Crowley, H J Eyre, B Stafford, K A Jaeckle, J J Townsend. J Neurooncol 1993
98
21

Epidemiology and etiology of meningioma.
Joseph Wiemels, Margaret Wrensch, Elizabeth B Claus. J Neurooncol 2010
598
21

Salvage chemotherapy with CPT-11 for recurrent meningioma.
Marc C Chamberlain, Denice D Tsao-Wei, Susan Groshen. J Neurooncol 2006
64
18

Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent WHO grade II or III meningioma.
Julia Furtner, Veronika Schöpf, Katharina Seystahl, Emilie Le Rhun, Roberta Rudà, Ulrich Roelcke, Susanne Koeppen, Anna Sophie Berghoff, Christine Marosi, Paul Clement,[...]. Neuro Oncol 2016
36
33

Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma.
Ziming Du, Malak Abedalthagafi, Ayal A Aizer, Allison R McHenry, Heather H Sun, Mark-Anthony Bray, Omar Viramontes, Revaz Machaidze, Priscilla K Brastianos, David A Reardon,[...]. Oncotarget 2015
88
18

Trabectedin has promising antineoplastic activity in high-grade meningioma.
Matthias Preusser, Sabine Spiegl-Kreinecker, Daniela Lötsch, Adelheid Wöhrer, Maria Schmook, Karin Dieckmann, Walter Saringer, Christine Marosi, Walter Berger. Cancer 2012
43
27

Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma.
David A Reardon, Andrew D Norden, Annick Desjardins, James J Vredenburgh, James E Herndon, April Coan, John H Sampson, Sridharan Gururangan, Katherine B Peters, Roger E McLendon,[...]. J Neurooncol 2012
49
24

Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea.
U M Schrell, M G Rittig, M Anders, U H Koch, R Marschalek, F Kiesewetter, R Fahlbusch. J Neurosurg 1997
132
18

Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations.
David E Reuss, Rosario M Piro, David T W Jones, Matthias Simon, Ralf Ketter, Marcel Kool, Albert Becker, Felix Sahm, Stefan Pusch, Jochen Meyer,[...]. Acta Neuropathol 2013
149
18

Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas.
Ganesh M Shankar, Malak Abedalthagafi, Rachael A Vaubel, Parker H Merrill, Naema Nayyar, Corey M Gill, Ryan Brewster, Wenya Linda Bi, Pankaj K Agarwalla, Aaron R Thorner,[...]. Neuro Oncol 2017
70
18

SMO mutation status defines a distinct and frequent molecular subgroup in olfactory groove meningiomas.
Julien Boetto, Franck Bielle, Marc Sanson, Matthieu Peyre, Michel Kalamarides. Neuro Oncol 2017
53
22

BAP1 mutations in high-grade meningioma: implications for patient care.
Ganesh M Shankar, Sandro Santagata. Neuro Oncol 2017
80
18

Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial.
Thomas Graillon, Marc Sanson, Chantal Campello, Ahmed Idbaih, Matthieu Peyre, Hadrien Peyrière, Noémie Basset, Didier Autran, Catherine Roche, Michel Kalamarides,[...]. Clin Cancer Res 2020
42
28

Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone.
S M Grunberg, M H Weiss, I M Spitz, J Ahmadi, A Sadun, C A Russell, L Lucci, L L Stevenson. J Neurosurg 1991
275
16

The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B.
S E Kaba, F DeMonte, J M Bruner, A P Kyritsis, K A Jaeckle, V Levin, W K Yung. Neurosurgery 1997
95
16

Medical therapies for meningiomas.
Patrick Y Wen, Eudocia Quant, Jan Drappatz, Rameen Beroukhim, Andrew D Norden. J Neurooncol 2010
102
16

mTORC1 inhibitors suppress meningioma growth in mouse models.
Doreen Pachow, Nadine Andrae, Nadine Kliese, Frank Angenstein, Oliver Stork, Annette Wilisch-Neumann, Elmar Kirches, Christian Mawrin. Clin Cancer Res 2013
70
16


Advances in meningioma genetics: novel therapeutic opportunities.
Matthias Preusser, Priscilla K Brastianos, Christian Mawrin. Nat Rev Neurol 2018
84
16

Successful treatment of multiple intracranial meningiomas with the antiprogesterone receptor agent mifepristone (RU486).
Mehdi Touat, Giuseppe Lombardi, Patrizia Farina, Michel Kalamarides, Marc Sanson. Acta Neurochir (Wien) 2014
32
31


Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma.
Warren P Mason, Fred Gentili, David R Macdonald, Subramanian Hariharan, Charlene R Cruz, Lauren E Abrey. J Neurosurg 2002
104
15

High incidence of activating TERT promoter mutations in meningiomas undergoing malignant progression.
Stéphane Goutagny, Jean C Nault, Maxime Mallet, Dominique Henin, Jessica Z Rossi, Michel Kalamarides. Brain Pathol 2014
160
15

Progesterone and estrogen receptors in meningiomas: prognostic considerations.
D W Hsu, J T Efird, E T Hedley-Whyte. J Neurosurg 1997
237
15

Pathological classification and molecular genetics of meningiomas.
Christian Mawrin, Arie Perry. J Neurooncol 2010
269
13


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.